(Albany) DelveInsight’s “Pulmonary Arterial Hypertension Pipeline Insight 2023” report offers extensive knowledge on more than 55+ companies and 55+ pipeline drugs within the landscape of Pulmonary Arterial Hypertension research. The Pulmonary Arterial Hypertension Pipeline report provides detailed profiles of the Pulmonary Arterial Hypertension pipeline drugs, encompassing both Pulmonary Arterial Hypertension clinical trials and nonclinical stage products. Additionally, it assesses the therapeutics based on product type, stage, route of administration, and molecule type. Furthermore, the report sheds light on inactive pipeline products in this field.

 

In the Pulmonary Arterial Hypertension Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Pulmonary Arterial Hypertension clinical trials studies, Pulmonary Arterial Hypertension NDA approvals (if any), and product development activities comprising the technology, Pulmonary Arterial Hypertension collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

 

To explore more information on the latest breakthroughs in the Pulmonary Arterial Hypertension Pipeline treatment landscape of the report, click here @ Pulmonary Arterial Hypertension Pipeline Outlook

 

Key Takeaways from the Pulmonary Arterial Hypertension Pipeline Report

• DelveInsight’s Pulmonary Arterial Hypertension Pipeline analysis depicts a robust space with 55+ active players working to develop 55+ pipeline treatment therapies.
• The leading Pulmonary Arterial Hypertension Companies are working in the market include Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others
• Promising Pulmonary Arterial Hypertension Pipeline Therapies in the various stages of development include Parenteral Treprostinil, Oral Treprostinil, Epoprostenol, AV-101, Macitentan, Selexipag, macitentan (ACT-064992), Sotatercept, LIQ861, and others
• Sotatercept is a first-in-class therapeutic fusion protein comprised of the extracellular domain of human activin receptor type IIA, fused to the Fc domain of human immunoglobulin G1 (IgG1). It provides balance of the growth-promoting activin growth differentiation factor pathway, and the growth-inhibiting BMP pathway by serving as a ligand trap for the TGF-β superfamily. The United States Food and Drug Administration (FDA) has granted Orphan Drug designation and Breakthrough Therapy designation to sotatercept for the treatment of PAH; the European Medicines Agency (EMA) has granted Priority Medicines (PRIME) designation to sotatercept for the treatment of PAH. Sotatercept is in Phase III clinical trial for the treatment of PAH.
• LIQ861 is an investigational, inhaled dry powder formulation of treprostinil designed using the Company’s novel PRINT technology and engineered with the goal of enhancing deep-lung delivery of treprostinil in PAH patients by means of a convenient, palm-sized dry powder inhaler. Liquidia resubmits New Drug Application for LIQ861 under the 505(b)(2) regulatory pathway for the treatment of pulmonary arterial hypertension (PAH).

 

Pulmonary Arterial Hypertension Overview

Pulmonary arterial hypertension (PAH) is a rare, progressive, and life-threatening blood vessel disorder. PAH is characterized by a thickening of the pulmonary vasculature, leading to restricted blood flow and elevated blood pressure within the pulmonary vessels.

 

For further information, refer to the detailed Pulmonary Arterial Hypertension Unmet Needs, Pulmonary Arterial Hypertension Market Drivers, and Pulmonary Arterial Hypertension Market Barriers, click here for Pulmonary Arterial Hypertension Ongoing Clinical Trial Analysis

 

Pulmonary Arterial Hypertension Emerging Drugs Profile

• Sotatercept: Acceleron Pharma
• LIQ861: Liquidia Technologies

 

Pulmonary Arterial Hypertension Pipeline Therapeutics Assessment

There are approx. 55+ Pulmonary Arterial Hypertension companies which are developing the therapies for Pulmonary Arterial Hypertension. The Pulmonary Arterial Hypertension companies which have their Pulmonary Arterial Hypertension drug candidates in the most advanced stage, i.e. Preregistration include, Liquidia Technologies.

 

Request a sample and discover the recent advances in Pulmonary Arterial Hypertension Ongoing Clinical Trial Analysis and Medications, click here @ Pulmonary Arterial Hypertension Treatment Landscape

 

Pulmonary Arterial Hypertension Pipeline Segmentation

• Assessment by Product Type
• Assessment by Stage and Product Type
• Assessment by Route of Administration
• Assessment by Stage and Route of Administration
• Assessment by Molecule Type
• Assessment by Stage and Molecule Type

 

Some of the Companies in the Pulmonary Arterial Hypertension Therapeutics Market include-

Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others

 

Dive deep into rich insights for drugs for Pulmonary Arterial Hypertension Pipeline, click here @ Pulmonary Arterial Hypertension Unmet Needs and Analyst Views

 

Scope of the Pulmonary Arterial Hypertension Pipeline Report

• Coverage- Global
• Pulmonary Arterial Hypertension Companies- Merck Sharp & Dohme, Acceleron Pharma, Liquidia Technologies, Gossamer Bio, Resverlogix, PhaseBio Pharmaceuticals, Pharmosa BioPharm, Complexa, Gmax Biopharm Australia, Mezzion, Radikal Therapeutics, Galectin Therapeutics, Altavant Sciences, Ribomic, and others
• Pulmonary Arterial Hypertension Pipeline Therapies- Parenteral Treprostinil, Oral Treprostinil, Epoprostenol, AV-101, Macitentan, Selexipag, macitentan (ACT-064992), Sotatercept, LIQ861, and others
• Pulmonary Arterial Hypertension Segmentation: Product Type, Molecule Type, Route of Administration

 

Got Queries? Find out the related information on Pulmonary Arterial Hypertension Mergers and acquisitions, Pulmonary Arterial Hypertension Licensing Activities @ Pulmonary Arterial Hypertension Emerging Drugs, and Recent Trends

 

Table of Content

1. Introduction
2. Pulmonary Arterial Hypertension Executive Summary
3. Pulmonary Arterial Hypertension: Overview
4. Pulmonary Arterial Hypertension Pipeline Therapeutics
5. Pulmonary Arterial Hypertension Therapeutic Assessment
6. Pulmonary Arterial Hypertension – DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. Sotatercept: Acceleron Pharma
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. GB-002: Gossamer Bio
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Apabetalone: Resverlogix
15. Drug profiles in the detailed report…..
16. Preclinical/Discovery Stage Products
17. R107: Radikal Therapeutics
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Pulmonary Arterial Hypertension Key Companies
21. Pulmonary Arterial Hypertension Key Products
22. Pulmonary Arterial Hypertension- Unmet Needs
23. Pulmonary Arterial Hypertension- Market Drivers and Barriers
24. Pulmonary Arterial Hypertension- Future Perspectives and Conclusion
25. Pulmonary Arterial Hypertension Analyst Views
26. Appendix

 

About Us             

DelveInsight is a leading healthcare focussed market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting-services